ANXV (a human recombinant Annexin A5) is well-tolerated and safe in Phase 1 First In Human clinical trial and is currently in Phase 2 in Retinal Vein Occlusion.

ANXV - Annexin

Anna Frostegaard 1,2; Susan Suchdev 1; Johan Frostegaard 2,1; Mario Fsadni 1; Anders Haegerstrand 1

Apr 6, 2023